-
Mashup Score: 3First-in-Class Bicycle Toxin Conjugate Targeting Nectin-4 Generates Excitement in Urothelial Carcinoma - 14 hour(s) ago
Oncologists detail how zelenectide pevedotin, which is under evaluation in the Duravelo-2 trial, could fill an unmet need in metastatic urothelial carcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3Education, Telehealth, and Access Initiatives Aim to Improve Cancer Care for Veterans - 13 day(s) ago
Manali I. Patel, MD, MPH, MS, details several interventions developed to better serve veterans with cancer who are experiencing economic, social, and geographic barriers to care.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Education, Telehealth, and Access Initiatives Aim to Improve Cancer Care for Veterans @manalipatelmd @stanfordmed @vapaloalto #oncology #MedTwitter #MedEd https://t.co/gmHV2AtkB7
-
-
Mashup Score: 4Discussions Swirl on the Role of PD-1 Inhibitors for Gastric/GEJ/ESCC Cancers With 1%-10% PD-L1 Expression - 14 day(s) ago
Nataliya Uboha, MD, PhD, and Robert Albert Anders, MD, PhD, unpack the unfavorable risk-benefit profile of PD-1 inhibitors in patients with certain PD-L1–negative gastrointestinal cancers and discussions from a recent ODAC meeting.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Discussions Swirl on the Role of PD-1 Inhibitors for Gastric/GEJ/ESCC Cancers With 1%-10% PD-L1 Expression @NataliyaUboha @UWCarbone @hopkinskimmel #oncology #MedTwitter #MedEd https://t.co/rx6tvGHKyL
-
-
Mashup Score: 3Education, Telehealth, and Access Initiatives Aim to Improve Cancer Care for Veterans - 15 day(s) ago
Manali I. Patel, MD, MPH, MS, details several interventions developed to better serve veterans with cancer who are experiencing economic, social, and geographic barriers to care.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Education, Telehealth, and Access Initiatives Aim to Improve Cancer Care for Veterans @manalipatelmd @stanfordmed @vapaloalto #oncology #MedTwitter #MedEd https://t.co/gmHV2AtkB7
-
-
Mashup Score: 4Discussions Swirl on the Role of PD-1 Inhibitors for Gastric/GEJ/ESCC Cancers With 1%-10% PD-L1 Expression - 23 day(s) ago
Nataliya Uboha, MD, PhD, and Robert Albert Anders, MD, PhD, unpack the unfavorable risk-benefit profile of PD-1 inhibitors in patients with certain PD-L1–negative gastrointestinal cancers and discussions from a recent ODAC meeting.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Discussions Swirl on the Role of PD-1 Inhibitors for Gastric/GEJ/ESCC Cancers With 1%-10% PD-L1 Expression @NataliyaUboha @UWCarbone @hopkinskimmel #oncology #MedTwitter #MedEd https://t.co/rx6tvGHKyL
-
-
Mashup Score: 3Education, Telehealth, and Access Initiatives Aim to Improve Cancer Care for Veterans - 24 day(s) ago
Manali I. Patel, MD, MPH, MS, details several interventions developed to better serve veterans with cancer who are experiencing economic, social, and geographic barriers to care.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Education, Telehealth, and Access Initiatives Aim to Improve Cancer Care for Veterans @manalipatelmd @stanfordmed @vapaloalto #oncology #MedTwitter #MedEd https://t.co/gmHV2AtkB7
-
-
Mashup Score: 11Fox Chase Researchers Present Findings on Uptake of Aspirin for Lynch Syndrome Chemoprevention at 2024 CGA-IGC Meeting - 1 month(s) ago
Researchers from Fox Chase Cancer will present a new study on the use of aspirin as a form of chemoprevention in patients with Lynch syndrome at the 2024 CGA-IGC Meeting.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Fox Chase Researchers Present Findings on Uptake of Aspirin for Lynch Syndrome Chemoprevention at 2024 CGA-IGC Meeting @FoxChaseCancer @CGAIGC #oncology #MedTwitter #MedEd https://t.co/8xh6wSFHPW
-
-
Mashup Score: 1
Daniel J. DeAngelo MD, PhD, discusses the potential role for INCA033989 as a disease-modifying therapy in CALR type 1–mutated myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Unlike the array of JAK inhibitors available for the treatment of patients with myelofibrosis, the novel monoclonal antibody INCA033989 may have disease-modifying potential among those expressing CALR type 1 mutations. #oncology #MedTwitter #MedEd https://t.co/hmMb1TzOYe https://t.co/74dG4xFWhZ
-
-
Mashup Score: 1
Daniel J. DeAngelo MD, PhD, discusses the potential role for INCA033989 as a disease-modifying therapy in CALR type 1–mutated myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Unlike the array of JAK inhibitors available for the treatment of patients with myelofibrosis, the novel monoclonal antibody INCA033989 may have disease-modifying potential among those expressing CALR type 1 mutations. #oncology #MedTwitter #MedEd https://t.co/hmMb1TzOYe https://t.co/74dG4xFWhZ
-
-
Mashup Score: 3First-in-Class Bicycle Toxin Conjugate Targeting Nectin-4 Generates Excitement in Urothelial Carcinoma - 2 month(s) ago
Oncologists detail how zelenectide pevedotin, which is under evaluation in the Duravelo-2 trial, could fill an unmet need in metastatic urothelial carcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
First-in-Class Bicycle Toxin Conjugate Targeting Nectin-4 Generates Excitement in Urothelial Carcinoma @DrTFriedlander @UCSFCancer @kalasri3 @thePMCF #oncology #MedTwitter #MedEd https://t.co/mf3jhWHT0E
-
First-in-Class Bicycle Toxin Conjugate Targeting Nectin-4 Generates Excitement in Urothelial Carcinoma @DrTFriedlander @UCSFCancer @kalasri3 @thePMCF #oncology #MedTwitter #MedEd https://t.co/mf3jhWHT0E